RNA Stock-Based Compensation
Atrium Therapeutics Inc · Stock-Based Compensation
RNA Stock-Based Compensation
Latest reported$7.68Mperiod ending
RNA FY Stock-Based Comp ($7.68M → $7.68M)
Annual stock-based compensation
More history is needed to export this chart.
RNA stock-based compensation history
Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 7,679,000 |